Myotonic Dystrophy: EPIC Functions at The Ottawa Hospital

In 2019, the Ottawa Hospital (TOH) introduced a new Electronic Health Record system called EPIC, to move documentation such as orders for blood work, prescriptions, notes and letters from paper-based to online digital formats. This involved a major investment in education and training of hospital staff.

 

A recent initiative highlights how EPIC functions can be tailored to improve the safety of patients with a rare muscle condition called myotonic dystrophy (DM). DM is a genetic condition that leads to muscle weakness and wasting, and to additional health issues such as cardiac arrhythmia, cataracts of the eyes, diabetes, constipation, and disrupted sleep. DM patients also respond with severe side effects to a range of medications and anaesthetics.

 

At the Neuromuscular Centre at TOH there are more than 50 patients with DM under the care of neuromuscular specialists, who aware of the specific risks and health issues associated with DM. However, DM patients frequently need to seek medical attention at other TOH departments, whose staff may not be aware of the DM diagnosis or the specific risks associated with prescriptions.

 

Inspired by a DM family from Ottawa, the TOH medical information team has designed a new EPIC functionality, so-called Best Practice Advisories (BPA), to keep DM patients safe throughout the hospital. Firstly, a side panel alert informs doctors and nurses accessing the patient’s records about the DM diagnosis and provides guidance through a specific “standards of care” document that has been devised by international experts together with the Myotonic Dystrophy Foundation. Secondly, a specific warning will be displayed if the doctor attempts to order a medication that is considered potentially unsafe for DM; to proceed with the order, they are required to acknowledge the warning and explain their reasons.

 

The new BPAs went live in June 2021. If successful, they may be adopted by other hospitals and organisations in Canada to keep DM patients safe.

 

The Neuromuscular Disease Network for Canada (NMD4C) is a network of clinicians, scientists, patients and patient advocacy groups, committed to improving the care, research, and treatment of neuromuscular diseases for all Canadians. The network is encouraged to see projects such as this that engage multiple stakeholders, identifying and addressing issues from different perspectives and fostering collaborations that deliver impactful outcomes.

 

For further information please contact:

James Davis, NMD4C Communications Coordinator

EPIC_DM

Read next...

MDC-grant-plan-2022

Clinical and Postdoctoral Research Fellowship Funding Competition from NMD4C, MDC, CSCN Now Open!

The NMD4C, in partnership with Muscular Dystrophy Canada (MDC) is now accepting applications for Post-doctoral Research Fellowships and Clinical Fellowships! These competitions are now open, and will close on November 14, 2022.

National Neuromuscular Lecture Series

National Neuromuscular Lecture Series Provides Training Opportunity for Neuromuscular Clinical Fellows

The NMD4C curriculum working group is pleased to share that the inaugural “National Neuromuscular Lecture Series” kicked off this August 12, 2022. This year-long training curriculum for current Canadian neuromuscular fellows has been developed in consultation with the directors of fellowship programs across Canada. The group decided on 41 topics which constitute a comprehensive neuromuscular knowledge base and identified subject-matter experts from across the country to deliver the weekly lectures.

imPORTND - soft launch image

imPORTND Patient-Oriented Research Training for Neuromuscular Disease Seeks Research Teams for Testing

The NMD4C is excited to introduce our online training platform “imPORTND”, created to help scientists engage with patient partners in research. These modules are designed for all neuromuscular research team members including researchers, staff, and patient partners. imPORTND has been co-developed with a team of expert patient partners, clinicians, and researchers, and offer two modules to help scientists engage with patient partners in research. It is the first patient-oriented research training that focuses specifically on neuromuscular disease.

Myotonic dystrophy foundation logo

2023 Myotonic Dystrophy Foundation Early Career Research Grant

The MDF will issue up to two two-year awards of up to $380,000 at $190,000 per award for early career scholars in the DM field for projects that focus on basic, translational and/or clinical research or care projects in myotonic dystrophy.

welcome to the team - Kevin LaFleur

NMD4C Hire Research Software Developer

The NMD4C are pleased to announce the hiring of research software developer Kevin LaFleur as the most recent addition to the network’s biobanking team! Kevin will develop the technical infrastructure for a centralized Canadian neuromuscular biobanking catalogue.

Global Alliance for DM Awareness Announces Areas of Focus for 2022

International Myotonic Dystrophy Awareness Day 2022 to Take Place September 15th

The NMD4C alongside Muscular Dystrophy Canada (MDC) are proud to be members of a global alliance of over 50 myotonic dystrophy-focused organizations who have once again united to celebrate Myotonic Dystrophy Families Day this past July 23rd, and International Myotonic Dystrophy Awareness Day on September 15th.